PHARMACOLOGICAL PROFILE OF THE NOVEL PUTATIVE ANXIOLYTIC AGENT 1-AMINO-5-BROMOURACIL

The newly synthesized compound, 1-amino-5-bromouracil (ABU CAS 127984- 93-4), showed unique anxiolytic activity in rats and mice. Its minimum effective dose was 10 mg/kg p.o. in the Geller type conflict test in rats, and it showed anxiolytic activity at a dose of 20 mg/kg ip. in t he Vogel type conflict test in mice. ABU also induced loss of the righ ting reflex in mice. The ED50, a dose level that induces loss of the r ighting reflex in 50 % of mice, was 86.4 mg/kg p. o. On the other hand , ABU showed only weak activities both potentiating the drug-induced a nesthesia and myorelaxing in comparison with diazepam. Furthermore ABU did not show an affinity for benzodiazepine receptor Thus, the pharma cological profile of ABU is concluded to be different from that of dia zepam.